The Invesco Health Care Fund underperformed its benchmark for the first quarter of 2025. Click here to read the full ...

At the heart of the Dutch court case on Humira is the question of whether there ought to be limits to what a company can ...

As global awareness of gender-specific medicine continues to rise, the women's health therapeutics market is entering a ...

Ironwood Pharmaceuticals, Inc.’s IRWD share price has surged by 5.57%, which has investors questioning if this is right time ...

Nearly everything looked great with AbbVie's (NYSE: ABBV) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune ...

An AbbVie research and development lab in San Francisco. (Brian L. Frank for The Wall Street Journal) Drugmaker AbbVie plans to invest more than $10 billion in domestic manufacturing and other ...

It beat convincingly on both the top and bottom lines. For its first quarter of this year, AbbVie's net revenue was $13.3 billion, representing a sturdy 8% improvement on a year-over-year basis.

Rob Stothard / Bloomberg via Getty Images AbbVie's first-quarter sales and adjusted earnings per share topped estimates. The drugmaker lifted its full-year adjusted EPS forecast by 10 cents.

AbbVie's first-quarter results improved with revenue growth powered by soaring sales for treatments in its immunology portfolio, prompting the company to raise its outlook for the year even as ...

Plus, AbbVie’s top-selling drug, Skyrizi, is made in the U.S., the CEO added. Nevertheless, AbbVie is bracing for potential near-term headwinds if pharmaceutical tariffs touch down, said CFO Reents.

AbbVie Inc. raised its profit outlook for the year on better-than-expected sales from newer autoimmune treatments, but warned its forecast doesn’t take into account any potential changes in ...

AbbVie's Q1 EPS of $2.46 beat estimates; sales rose 8.4% to $13.34 billion, topping consensus of $12.92 billion. Skyrizi and Rinvoq sales surged 70.5% and 57.2%, while Humira dropped 50.6%. Don ...